Theriva Biologics Inc
TOVX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.13M
Close$
$0.86
204% upside
Current Fair Value
204% upsideUndervalued by 204% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.13 Million |
|---|---|
| Enterprise Value | $-2,235,647.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.08 |
| Beta | 1.18 |
| Outstanding Shares | 41,072,725 |
Return
| Return on Equity | -149.16% |
|---|---|
| Return on Assets | -60.05% |
| Return on Invested Capital | -77.30% |
Valuation & Multiples
| P/E Ratio | -0.54 |
|---|---|
| PEG | 1.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -7.45 |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.92 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.19%▲ 5.52% |
|---|---|
| Total Invested | $385,352▲ 41.48% |
| Investors Holding | 200% |
ESG Score
No data
About Theriva Biologics Inc
10 employees
CEO: Steven Shallcross Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates ...